Stellar Biotechnologies, Inc. | Business Contracts

Lease Extending and Amending Agreement dated as of December 31, 2022 by and between Edesa Biotech Research, Inc. and 1968160 Ontario, Inc (Filed With SEC on February 10, 2023)

Third Amendment to Exclusive License Agreement, dated October 26, 2022, by and between the Registrant and Yissum Research Development Company (Filed With SEC on December 16, 2022)

Form of U.S. Subscription Agreement (Filed With SEC on November 3, 2022)

Amendment to Employment Agreement, entered into on April 12, 2022, by and between Michael Brooks and Edesa Biotech USA, Inc (Filed With SEC on May 13, 2022)

Strategic Innovation Fund Agreement among Edesa Biotech Research, Inc., Edesa Biotech, Inc., and her Majesty the Queen in right of Canada as represented by the Minister of... (Filed With SEC on February 3, 2021)

Amendment to Financial Advisory Agreement, dated December 20, 2019, between Edesa Biotech, Inc. and Brookline Capital Markets, a division of Arcadia Securities, LLC (Filed With SEC on January 6, 2020)

Form of Non-U.S. Subscription Agreement (Filed With SEC on November 3, 2022)

Form of Class B Warrant (Filed With SEC on November 3, 2022)

Form of Class A Warrant (Filed With SEC on November 3, 2022)

Amendment to Employment Agreement, entered into on April 12, 2022, by and between Kathi Niffenegger and Edesa Biotech USA, Inc (Filed With SEC on May 13, 2022)

Amendment to Employment Agreement, entered into on April 12, 2022, by and between Par Nijhawan and Edesa Biotech, Inc (Filed With SEC on May 13, 2022)

Form of Private Placement Warrant (Filed With SEC on March 23, 2022)

Form of Pre-Funded Warrant (Filed With SEC on March 23, 2022)

Form of Placement Agent Warrant (Filed With SEC on March 23, 2022)

Form of Securities Purchase Agreement, dated March 21, 2022, by and between the Company and the Purchaser (Filed With SEC on March 23, 2022)

First Amendment to Equity Distribution Agreement, dated as of March 4, 2022, by and between Edesa Biotech, Inc. and RBC Capital Markets, LLC (Filed With SEC on March 4, 2022)

Equity Distribution Agreement, dated as of November 22, 2021, by and between Edesa Biotech, Inc. and RBC Capital Markets, LLC (Filed With SEC on November 22, 2021)

Amendment to Employment Agreement, entered into on March 19, 2021, by and between Michael Brooks and Edesa Biotech, Inc (Filed With SEC on May 14, 2021)

Amendment to Employment Agreement, entered into on March 19, 2021, by and between Kathi Niffenegger and Edesa Biotech USA, Inc (Filed With SEC on May 14, 2021)

Amendment to Employment Agreement, entered into on March 19, 2021, by and between Par Nijhawan and Edesa Biotech, Inc (Filed With SEC on May 14, 2021)

Amendment No. 1 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan (Filed With SEC on April 23, 2021)

Exclusive License Agreement, dated as of March 16, 2021, by and between the Edesa Biotech Research, Inc. andDr. Saul Yedgar (Filed With SEC on March 22, 2021)

Form of Underwriter Warrant (Filed With SEC on February 26, 2021)

Underwriting Agreement (Filed With SEC on February 26, 2021)

Employment Agreement by and between the Company and Kathi Niffenegger, dated December 1, 2020 (Filed With SEC on December 7, 2020)

Equity Distribution Agreement, dated as of September 28, 2020, by and between Edesa Biotech, Inc. and RBC Capital Markets, LLC (Filed With SEC on September 28, 2020)

Securities Purchase Agreement by and between Edesa Biotech, Inc. and NovImmune SA dated April 17, 2020 (Filed With SEC on April 23, 2020)

Purchase Agreement by and between Edesa Biotech Research, Inc. and NovImmune SA dated April 17, 2020 (Filed With SEC on April 23, 2020)

License Agreement by and between Edesa Biotech Research, Inc. and NovImmune SA dated April 17, 2020 (Filed With SEC on April 23, 2020)

Form of Class A Purchase Warrant to be issued to investors (Filed With SEC on January 6, 2020)

(Filed With SEC on January 6, 2020)

Form of Class B Purchase Warrant to be issued to investors (Filed With SEC on January 6, 2020)

Form of Warrant to be issued to Brookline Capital Markets, a division of Arcadia Securities, LLC (Filed With SEC on January 6, 2020)

Financial Advisory Agreement, dated November 5, 2019, between Edesa Biotech, Inc. and Brookline Capital Markets, a division of Arcadia Securities, LLC (Filed With SEC on January 6, 2020)

Form of Subscription Agreement between Edesa Biotech, Inc. and certain investors (Filed With SEC on January 6, 2020)

2019 Equity Incentive Compensation Plan (Filed With SEC on October 25, 2019)

Lease, dated as of January 1, 2017, by and between the Registrant and 1968160 Ontario Inc (Filed With SEC on August 30, 2019)

License and Development Agreement, dated as of August 27, 2017, by and between the Registrant and Pendopharm, a division of Pharmascience Inc (Filed With SEC on August 30, 2019)

Exclusive License Agreement, dated as of June 15, 2016, by and between the Registrant and Cipher Pharmaceuticals Inc (Filed With SEC on August 30, 2019)

Second Amendment to Exclusive License Agreement, dated May 7, 2017, by and between the Registrant and Yissum Research Development Company (Filed With SEC on August 30, 2019)

First Amendment to Exclusive License Agreement, dated April 3, 2017, by and between the Registrant and Yissum Research Development Company (Filed With SEC on August 30, 2019)

Exclusive License Agreement, dated as of June 29, 2016, by and between the Registrant and Yissum Research Development Company (Filed With SEC on August 30, 2019)

Form of Indemnification Agreement, by and between the Company and each of its directors and executive officers (Filed With SEC on June 20, 2019)

Employment Agreement, dated as of June 14, 2019, by and between the Registrant and Michael Brooks (Filed With SEC on June 20, 2019)

Employment Agreement, dated as of June 14, 2019, by and between the Registrant and Dr. Pardeep Nijhawan (Filed With SEC on June 20, 2019)

Employment Agreement, dated as of June 7, 2019, by and between the Company and Kathi Niffenegger (Filed With SEC on June 10, 2019)

Share Exchange Agreement, dated as of March 7, 2019, by and between Stellar Biotechnologies Inc., Edesa Biotech Inc. and the Edesa Shareholders (Filed With SEC on March 8, 2019)

Stellar Biotechnologies, Inc. (47)